SEATTLE, June 01, 2021, (MEDGADGET) — Overview:
Tauopathies are a group of around 20 neurodegenerative diseases marked by the accumulation of tau protein in the brain. There are currently only a few therapeutics available for the treatment of tauopathies. The growing number of patients suffering from progressive supranuclear palsy (PSP) and frontotemporal lobar degeneration (FTLD-TAU) corticobasal degeneration is expected to drive global tauopathies treatment market growth significantly. PSP is a four-repeat (4R) tauopathy with a distinct biochemical profile and a preponderance of four-repeat tau isoforms. For instance, According to a report by the National Organization for Rare Disorders, PSP is estimated to affect around 5 in 100,000 people worldwide.
For More Information, Request Sample Copy Of Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/3995
Alzheimer’s disease (AD) is the most prevalent tauopathy and a common cause of dementia in the elderly, according to the BioMed Central (BMC) journal. The development of ß- amyloid (Aß) and tau pathology is a hallmark of Alzheimer’s disease, which is a chronic, incurable degenerative disease of the brain. There are still no disease-modifying medications available for Alzheimer’s disease, with only symptomatic therapies attempting to alleviate the neurotransmitter disruption. Despite rigorous clinical testing, no major new Alzheimer’s treatment has been released in the past 15 years. Since the last symptomatic AD treatment was licensed, the drug pipeline has been flooded by around 400 unsuccessful clinical trials.
Major factors such as ongoing research and development initiatives to produce new medicines, as well as the rising incidences of dementia, are expected to propel the global tauopathies treatment market growth over the forecast period. For instance, according to the World Health Organization (WHO), in 2019, around 50 million people worldwide were diagnosed with dementia, with over 10 million new cases diagnosed each year.
Impact of Coronavirus (Covid-19) Pandemic
The global spread of COVID-19 has had a huge impact on the development of the global tauopathies treatment market. It is difficult for researchers and key market players to secure funds for clinical trials and the discovery and development of a COVID-19 vaccine. Researchers are working to figure out how this lethal virus affects patients who have Alzheimer’s disease and other neurodegenerative disorders.
The report’s comprehensive edition would include the effects of COVID-19 as well as possible improvements in the market’s future outlook, taking into account technical, societal, political, and economic factors.
The global tauopathies treatment market is expected to be accounted around US$ 712.7 million in 2020 and is estimated to grow at a CAGR of 10.07% over the forecast period (2020-2027).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/3995
The global tauopathies treatment market is expected to drive growth due to rising introduction of new medications and treatments in the market during the forecast period.
Clinical trial approvals are expected to propel growth and offer attractive growth opportunities for market players over the forecast period in the global tauopathies treatment market.
For instance, in November 2017, Cortice Biosciences presented results from a placebo-controlled phase I double-blinded clinical trial assessing ‘TPI 287’. TPI 287 is a brain penetrable novel microtubule-stabilizing agent for the treatment of corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzheimer’s disease. The three of these conditions are known as ‘tauopathies,’ which are diseases with little cure that are characterized by progressive neurodegeneration that ultimately leads to death.
Moreover, Companies are working to synergize their respective resources and collaboratively build on the potential since this epidemic is a resource expensive and dangerous investment. For instance, in July 2019, REGENXBIO Inc. and Neurimmune AG entered a development and commercialization license agreement to determine and co-develop novel AAV gene therapies by making use of NAV Vectors. Human antibodies can be delivered alongside targets related to chronic neurodegenerative disorders, such as tauopathies, by the firms.
Furthermore, in February 2020, Oligomerix, Inc. presented efficacy data in two pre-clinical models of tauopathy. The findings were presented by the company at the TAU2020 Global Conference. According to Oligomerix’s reports, their lead compound reduced soluble levels of tau self-association and induced a dose-dependent decrease in insoluble and phosphorylated insoluble tau aggregates in the brains of tau mice, which reflects tauopathy in Alzheimer’s disease (AD).
Furthermore, shortage of licensed medicines for tauopathies treatment, is a major factor which is expected to hinder the growth of the global tauopathies treatment market over the forecast period. Moreover, delays in diagnosis and a lack of knowledge of the cellular pathways involved in pathogenic tau-induced disruption and neuronal death, which is also expected to hamper the growth of the global tauopathies treatment market.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/tauopathies-treatment-market-3264
In 2019, North America dominated the tauopathies treatment market, and this domination is expected to continue over the forecast period. This is partly due to the fact that therapy rates are considerably higher in this area over in other economies. For instance, in January 2020, Pfizer’s asset of Parkinson’s and Alzheimer’s was acquired by Biogen for US$ 710 million. The company’s aim behind this acquisition is to develop CNS-penetrate inhibitor of CK1 for patients with neurological and behavioral neurological symptoms in various neurological and psychiatric diseases.
Moreover, the tauopathies treatment market in Europe is expected to witness significant growth due to rising investments by government’s authorities and major pharmacy companies for advanced treatment of tauopathies. For instance, in January 2019, Aquinnah Pharmaceuticals received a grant of US$ 750,000 from the Tau Consortium and the Alzheimer’s Association to advance novel therapies for tauopathy diseases. Aquinnah has created neuronal models that mimic the human tau stress granule pathology with this funding. The firm is also interested in the identification of molecules with the ability to be transformed into new drugs.
- By Disease: Frontotemporal Degeneration, Alzheimer’s disease, Other Neurodegenerative Diseases.
- By Distribution Channel: Hospital Pharmacy, Online Sales, and Retail Pharmacy.
Key players are dominating in the global tauopathies treatment market such as Avanir Pharmaceuticals, Inc., AB Science, Otsuka Pharmaceutical Co., Ltd., Sellas, TauRx, Selvita S.A, Catalent Inc., Bristol-Myers Squibb Company, SK Biopharmaceuticals Co. and Chronos Therapeutics Limited, Ltd.
- Global Tauopathies Treatment Market, By Disease:
- Frontotemporal Degeneration
- Pick’s Disease
- Corticobasal Degeneration (CBD)
- Progressive Supranuclear Palsy (PSP)
- Alzheimer’s Disease
- Other Neurodegenerative Diseases
- Frontotemporal Degeneration
- Global Tauopathies Treatment Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Sales
- Global Tauopathies Treatment Market, By Region:
- North America
- Asia Pacific
- Latin America
- Middle East
- Company Profiles
Have a Look at Related Research Insights:
Toxoplasmosis Treatment Drugs Market Growth Forecast from 2021 to 2027
India Mucormycosis Treatment Market Growth Forecast from 2021 to 2027
Urea Cycle Disorders Treatment Market Growth Forecast from 2021 to 2027
Cholangiocarcinoma Market Growth Forecast from 2021 to 2027
Post-traumatic Stress Disorder Treatment Market Growth Forecast from 2021 to 2027
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027